# Intra-Erythrocyte Dexamethasone Sodium Phosphate in Ataxia Telangiectasia Patients

> **NCT02770807** · PHASE3 · COMPLETED · sponsor: **Quince Therapeutics S.p.A.** · enrollment: 176 (actual)

## Conditions studied

- Nervous System Disease
- Genetic Syndrome

## Interventions

- **DRUG:** EryDex Low dose DSP
- **DRUG:** EryDex High dose DSP
- **DRUG:** Pooled Placebo

## Key facts

- **NCT ID:** NCT02770807
- **Lead sponsor:** Quince Therapeutics S.p.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-02
- **Primary completion:** 2021-05-13
- **Final completion:** 2021-05-13
- **Target enrollment:** 176 (ACTUAL)
- **Last updated:** 2024-05-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02770807

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02770807, "Intra-Erythrocyte Dexamethasone Sodium Phosphate in Ataxia Telangiectasia Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02770807. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*